Paclitaxel combined with hyarulonic acid as the new drug for peritoneal dissemination of gastric cancer.

点击翻译按钮获取中文摘要

Intraperitoneal chemotherapy has been shown to be clinically useful for peritoneal matastais. In this study, we hypothesized that high molecular weight Hyarulonic Acid may retain the intraperitoneally administrated anticancer drugs in abdominal cavity and enhance the anti-tumor effects, and examined the effect of Non-Animal Stabilized Hyarulonic Acid (NASHA) (Q-Med Sweden). In fact, the addition of 5% NASHA suppressed the development of peritoneal nodules of MKN45 inplanted in nude mice significantly greater than paclitaxel or cisplatin alone. NASHA also increased the volume of fluid recovered from the mice. Intraperitoneal administration paclitaxel or cisplatin combined with NASHA can be a hopeful strategy as the treatment of peritoneal dissemination.